Logo-apb
Adv Pharm Bull. 2017;7(4): 531-546.
doi: 10.15171/apb.2017.065
PMID: 29399543
PMCID: PMC5788208
Scopus ID: 85043400933
  Abstract View: 2979
  PDF Download: 1815

Review Article

The Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles on Hematopoietic Stem Cells Fate

Hamze Timari 1, Karim Shamsasenjan 1*, Aliakbar Movassaghpour 2, Parvin Akbarzadehlaleh 3, Davod Pashoutan Sarvar 1, Sara Aqmasheh 1

1 Stem Cell Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Hematology Oncology Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
*Corresponding Author: Email: shamsk@tbzmed.ac.ir

Abstract

Hematopoietic stem cells (HSCs) are multipotent stem cells, with self-renewal ability as well as ability to generate all blood cells. Mesenchymal stem cells (MSCs) are multipotent stem cells, with self-renewal ability, and capable of differentiating into a variety of cell types. MSCs have supporting effects on hematopoiesis; through direct intercellular communications as well as secreting cytokines, chemokines, and extracellular vesicles (EVs). Recent investigations demonstrated that some biological functions and effects of MSCs are mediated by their EVs. MSC-EVs are the cell membrane and endosomal membrane compartments, which are important mediators in the intercellular communications. MSC-EVs contain some of the molecules such as proteins, mRNA, siRNA, and miRNA from their parental cells. MSC-EVs are able to inhibit tumor, repair damaged tissue, and modulate immune system responses. MSC-EVs compared to their parental cells, may have the specific safety advantages such as the lower potential to trigger immune system responses and limited side effects. Recently some studies demonstrated the effect of MSC-EVs on the expansion, differentiation, and clinical applications of HSCs such as improvement of hematopoietic stem cell transplantation (HSCT) and inhibition of graft versus host disease (GVHD). HSCT may be the only therapeutic choice for patients who suffer from malignant and non-malignant hematological disorders. However, there are several severe side effects such GVHD that restricts the successfulness of HSCT. In this review, we will discuss the most important effects of MSCs and MSC-EVs on the improvement of HSCT, inhibition and treatment of GVHD, as well as, on the expansion of HSCs.
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 2980

Your browser does not support the canvas element.


PDF Download: 1815

Your browser does not support the canvas element.

Submitted: 20 Sep 2017
Revision: 25 Nov 2017
Accepted: 28 Nov 2017
ePublished: 31 Dec 2017
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)